Role of p53 family proteins in metformin anti-cancer activities

38Citations
Citations of this article
76Readers
Mendeley users who have this article in their library.

Abstract

Metformin has been used as therapy for type 2 diabetes for many years. Clinical and basic evidence as indicated that metformin has anti-cancer activities. It has been well-established that metformin activates AMP-activated protein kinase (AMPK), which in turn regulates energy homeostasis. However, the mechanistic aspects of metformin anti-cancer activity remain elusive. p53 family proteins, including p53, p63 and p73, have diverse biological functions, including regulation of cell growth, survival, development, senescence and aging. In this review, we highlight the evidence and mechanisms by which metformin inhibits cancer cell survival and tumor growth. We also aimed to discuss the role of p53 family proteins in metformin-mediated suppression of cancer growth and survival.

Author supplied keywords

Cite

CITATION STYLE

APA

Yi, Y., Zhang, W., Yi, J., & Xiao, Z. X. (2019). Role of p53 family proteins in metformin anti-cancer activities. Journal of Cancer. Ivyspring International Publisher. https://doi.org/10.7150/jca.30659

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free